<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
@font-face
{font-family:"Times New Roman \(Body CS\)";}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle19
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:30615523;
mso-list-template-ids:-646563306;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:198934255;
mso-list-type:hybrid;
mso-list-template-ids:-784179368 -1236619302 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;
mso-fareast-font-family:Calibri;
mso-bidi-font-family:"Times New Roman \(Body CS\)";}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l2
{mso-list-id:202449317;
mso-list-type:hybrid;
mso-list-template-ids:-191440678 -1236619302 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l2:level1
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;
mso-fareast-font-family:Calibri;
mso-bidi-font-family:"Times New Roman \(Body CS\)";}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l3
{mso-list-id:676688469;
mso-list-template-ids:131232106;}
@list l3:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l4
{mso-list-id:1192181658;
mso-list-type:hybrid;
mso-list-template-ids:1446279452 -1236619302 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l4:level1
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;
mso-fareast-font-family:Calibri;
mso-bidi-font-family:"Times New Roman \(Body CS\)";}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l5
{mso-list-id:1653872791;
mso-list-type:hybrid;
mso-list-template-ids:-530013846 -1236619302 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l5:level1
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;
mso-fareast-font-family:Calibri;
mso-bidi-font-family:"Times New Roman \(Body CS\)";}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l6
{mso-list-id:1694456957;
mso-list-template-ids:-770690120;}
@list l6:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l6:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l6:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7
{mso-list-id:2129160712;
mso-list-type:hybrid;
mso-list-template-ids:592903324 -1236619302 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l7:level1
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;
mso-fareast-font-family:Calibri;
mso-bidi-font-family:"Times New Roman \(Body CS\)";}
@list l7:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l7:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l7:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l7:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l7:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l7:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l7:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l7:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="http://www.fahsbeckfund.org/grant_programs.html" target="_blank">Fahs-Beck Fund for Research and Experimentation: Faculty/Post-Doctoral Grant Program (Fahs-Beck Fellows)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Grants of up to $25,000 are available to help support the research of faculty members or post-doctoral researchers of accredited universities or colleges in the United States and Canada.
Areas of interest for funding are: studies to develop, refine, evaluate, or disseminate interventions and preventive/intervention to address social, psychological, behavioral or public health problems affecting children, adults, couples, families, and communities
with outcomes that have the potential add to the knowledge base for services and program development. Community engaged research is highly valued.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due April 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: March 22.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">UF CTSI Learning Health System Initiative: Translational Pilot (RFA attached)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The UF CTSI Learning Health System Program is pleased to invite applications for Translational Pilot Awards that use a “learning health system” approach to align research and clinical
operations to improve health outcomes and advance health equity using informatics, stakeholder engagement, implementation science and other methodologies to address one or more priority areas at UF Health including <b>potentially preventable admissions and
readmissions, decision support and/or particular conditions including: hypertension, diabetes, and opioid and other substance use</b>. <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Two 12-month awards of up to $50,000 each are available for pilot projects that address health-related research questions developed in collaboration with clinicians, patients and community
groups or other stakeholders. Research teams should demonstrate an established partnership with clinicians, patients, and other stakeholders as appropriate for the research. Once complete, these pilot projects should provide a solid foundation on which to
base applications for extramural funding. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due April 2, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: March 22.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.jsmf.org/apply/opportunity/">James S. McDonnell Foundation Opportunity Awards: Understanding Human Cognition</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The James S. McDonnell Foundation (JSMF) supports research on understanding human cognition across the fields of cognitive science, cognitive psychology and developmental science. The
Opportunity Awards were initiated because the foundation believes the time is right to advance the understanding of human cognition and behavior via a developmental science approach. With the Opportunity Awards, JSMF is seeking to fund projects leading to
<b>new</b> conceptual and empirical studies of cognition and behavior that recognize the dynamic nature of cognition and behavior, are situated in real world contexts, cross levels of analysis, unite traditionally separate domains of inquiry (e.g. vision and
speech), embrace complexity, and consider how behavior is influenced by interactions among individuals.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">$250,000 / 2-4 year projects.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due April 9, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: March 29.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2021-02/GMG_2021-Oncology-G_PCF-PfizerHealthEquityChallengeAwards.pdf?qtsGoIlXRCBA0eAJLsWvR2eU1grK9dLM">Prostate Cancer Foundation–Pfizer
Health Equity Challenge Awards</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The intent of this Request for Proposal is to support general research projects that will improve the understanding of or reduce disparities in the diagnosis, management, and outcomes
of prostate cancer patients in minority and underserved communities. General research proposals in the following topic areas are of particular interest:
<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Identification of barriers in the delivery of equitable healthcare
<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Health services research programs to study and optimize care delivery<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">$100,000–$150,000 / 1 year projects<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due April 9, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: March 29.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.samhsa.gov/grants/grant-announcements/ti-21-003">Provider’s Clinical Support System – Universities</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The <b>Substance Abuse and Mental Health Services Administration</b>, Center for Substance Abuse Treatment, is accepting applications for fiscal year 2021 Provider’s Clinical Support System
– Universities grants. The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder seeking or receiving MAT through ensuring the
<b>education and training of students in the medical, physician assistant, and nurse practitioner fields</b>. This program’s focus is to
<b>ensure students fulfill the training requirements needed to obtain a DATA waiver to prescribe MAT in office-based settings</b>.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The desired outcomes include:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l3 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">an increase in the number of individuals completing the training requirements for the DATA waiver;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">an increase the number of individuals with a DATA waiver; and<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">an ultimate increase in those prescribing.<o:p></o:p></span></li></ol>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Eligible applicants are medical schools, physician assistant schools, and schools of nursing (programs for nurse practitioners).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">3-year projects / $150,000 per year.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due April 20, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: April 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.alzdiscovery.org/research-and-grants/funding-opportunities/harrington" target="_blank">ADDF-Harrington Scholar Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and
committed project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. Average award: Up to $600,000 over 2 years with dedicated support from
a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Funding Priorities</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Drug Targets</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The 2021 ADDF-Harrington Scholar RFP places high priority on targets related to
<b>emerging therapeutic areas</b> for dementia, particularly:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><b><u><span style="font-size:12.0pt;font-family:Palatino">Epigenetics</span></u></b><span style="font-size:12.0pt;font-family:Palatino"> (including nucleosome dynamics, chromatin remodeling, DNA methylation,
histone modifications [methylation, acetylation, phosphorylation, ubiquitylation, sumoylation], bromodomain protein modulators, isocitrate dehydrogenase modulators)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><b><u><span style="font-size:12.0pt;font-family:Palatino">Proteostasis</span></u></b><span style="font-size:12.0pt;font-family:Palatino"> (including autophagy, lysosomal biogenesis, proteasomal degradation,
post-translational modification associated with proteostasis, protein folding/misfolding, ER stress, extracellular clearance)<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Other Novel Targets are Encouraged</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These include, but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Neurovascular health<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Neuroprotection<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Synaptic activity and neurotransmitters<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Inflammation<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Mitochondria & metabolic function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">ApoE<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Other aging targets (e.g. senescent cells)<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Any therapeutic target that has a
<b>clear marker of target engagement</b> or one in development will be considered of high priority.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due April 23, 2021. Application due July 30, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for letter of intent: April 12.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.pcori.org/funding-opportunities/announcement/engagement-award-special-cycle-building-capacity-PCOR-CER-COVID19-2021">PCORI Engagement Award Special Cycle: Building
Capacity for PCOR/CER for Topics Related to COVID-19</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Building Capacity for PCOR/CER for Topics Related to COVID-19</span></b><span style="font-size:12.0pt;font-family:Palatino"> is a research support – not research—special funding opportunity
for projects up to 18 months in duration and up to $200,000 in total costs. This special funding opportunity will support projects that enable organizations and communities to build their capacity and skills to participate across all phases of the PCOR/CER
process on topics that address health outcomes related to COVID-19. Projects will also provide an understanding of the impact of stakeholder engagement strategies within different settings and stakeholder groups focused on this special area of interest.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">In the context of the Engagement Awards program, capacity building to support research refers to the following types of projects:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l2 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Projects that focus on building the knowledge, competencies, and abilities of patients and other stakeholders to be meaningful partners
in PCOR/CER with researchers throughout the research process, from topic selection through design and conduct of research to dissemination or implementation of results.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l2 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Projects that strengthen the skills of researchers to be better partners with patients and other stakeholders involved in PCOR/CER.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l2 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Projects that support the expansion of use or adoption of existing engagement tools and resources to build capacity for PCOR/CER
in a new population or geographic area.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This is an opportunity to explore and address the urgent and unique needs to
<i>build capacity for</i> <i>stakeholder engagement in PCOR/CER</i> specifically related to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l7 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Long-term effects of post-acute COVID-19;<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l7 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Impact of COVID-19 on disproportionately affected populations;<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l7 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Impact of COVID-19 on social isolation and loneliness (mental health and well-being); and<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l7 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Engaging, educating, and promoting informed decision making around COVID-19 vaccines.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Other relevant topics related to COVID-19 health outcomes with appropriate justification will also be considered.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">$200,000 / 18-month projects.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 24, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: May 11.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.pcori.org/funding-opportunities/announcement/engagement-award-special-cycle-building-capacity-PCOR-CER-IDD-2021">PCORI Engagement Award Special Cycle: Building Capacity
for PCOR/CER in Intellectual and Developmental Disabilities</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This special funding opportunity will support projects that enable organizations and communities to build their capacity and skills to participate across all phases of the PCOR/CER process
on topics that address health outcomes related to intellectual and developmental disabilities (IDD). Projects will also provide an understanding of the impact of stakeholder engagement strategies within different settings and stakeholder groups focused on
this special area of interest. In the context of the Engagement Awards program, capacity building to support research refers to the following types of projects:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l1 level1 lfo7"><span style="font-size:12.0pt;font-family:Palatino">Projects that focus on building the knowledge, competencies, and abilities of patients and other stakeholders to be meaningful partners
in PCOR/CER with researchers throughout the research process, from topic selection through design and conduct of research to dissemination or implementation of results.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l1 level1 lfo7"><span style="font-size:12.0pt;font-family:Palatino">Projects that strengthen the skills of researchers to be better partners with patients and other stakeholders involved in PCOR/CER.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l1 level1 lfo7"><span style="font-size:12.0pt;font-family:Palatino">Projects that support the expansion of use or adoption of existing engagement tools and resources to build capacity for PCOR/CER
in a new population or geographic area.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This is an opportunity to
<i>build capacity for stakeholder engagement with PCOR/CER in IDD</i> on topics such as:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l4 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Addressing health equity and advancing IDD health outcomes for vulnerable populations<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l4 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Leveraging community-based and patient-centered models of care delivery<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l4 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Challenges related to clinical care delivery and access<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l4 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Telehealth solutions<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l4 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Transition to adulthood<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l4 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Caregiver needs and access to wraparound support<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l4 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Patient needs and preferences<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Other relevant topics related to IDD health outcomes with appropriate justification are welcomed.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">$250,000 / 2-year projects.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 24, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: May 11.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://anr.rwjf.org/viewCfp.do?cfpId=1571&cfpOverviewId=" target="_blank">Robert Wood Johnson Foundation's Systems for Action: Systems and Services Research to Build a Culture
of Health</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Achieving racial equity and health equity in American communities requires effective solutions to the “wrong-pocket problem”: we invest in systems that are designed to improve social and
economic conditions—such as housing, transportation, education, income, and employment assistance; child and family supports; and legal and criminal justice services—but the financial benefits of these often flow elsewhere, in reduced costs for medical care
from diseases and injuries prevented. This creates imbalances in power, information, and financial resources that exist across medical, social, and public health systems—a fundamental problem that confronts many attempts at meaningful cross-sector collaboration.
Such solutions must allow collaborating organizations to equitably share in the costs and the benefits of multisector collaborative initiatives, and to share in the power and influence that govern these initiatives. This call for proposals will provide funding
for new research to rigorously test and evaluate innovative solutions to the wrong-pocket problem that persists across health and social service systems. This call for proposals will support studies that can be completed over a 36-month period with up to $500,000
in total funding from RWJF. Up to four awards will be selected for funding under this solicitation.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 9, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: May 26.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-164.html">Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21 / R33 – Clinical Trial
Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Agency for Healthcare Research and Quality’s mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within
the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving
quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded
activities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires July 18, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for June 16 due date: June 3.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69">CoM’s
unofficial funding opportunities blog</a>.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>